Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 52-Week High – What’s Next?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $834.22 and last traded at $840.4730, with a volume of 94615 shares trading hands. The stock had previously closed at $810.24.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Barclays lowered their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Cantor Fitzgerald upped their target price on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. JPMorgan Chase & Co. cut their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Finally, Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research report on Tuesday, July 7th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $801.70.

Regeneron Pharmaceuticals Price Performance

The business has a fifty day moving average price of $683.57 and a 200 day moving average price of $714.66. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The company has a market capitalization of $86.38 billion, a price-to-earnings ratio of 20.71, a price-to-earnings-growth ratio of 1.37 and a beta of 0.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the prior year, the firm posted $12.81 EPS. Regeneron Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock valued at $1,090,030 over the last quarter. Corporate insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $5,682,636,000. Norges Bank bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $1,012,296,000. Price T Rowe Associates Inc. MD boosted its holdings in Regeneron Pharmaceuticals by 142.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after buying an additional 1,144,887 shares in the last quarter. Nuveen LLC grew its position in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after buying an additional 835,240 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $473,872,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.